NAFTIN Drug Patent Profile

Which patents cover Naftin, and what generic alternatives are available?

Naftin is a drug marketed by Legacy Pharma and is included in three NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has three patent family members in three countries.

The generic ingredient in NAFTIN is naftifine hydrochloride. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naftifine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naftin

A generic version of NAFTIN was approved as naftifine hydrochloride by SUN PHARMA CANADA on January 6^th, 2016.

Summary for NAFTIN

International Patents:	3
US Patents:	6
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	8
Patent Applications:	947
Drug Prices:	Drug price information for NAFTIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NAFTIN
What excipients (inactive ingredients) are in NAFTIN?	NAFTIN excipients list
DailyMed Link:	NAFTIN at DailyMed

See drug prices for NAFTIN

Recent Clinical Trials for NAFTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Therapeutics, Inc.	Phase 1
Genzum Life Sciences	Phase 3
GenZum Life Sciences LLC	Phase 3

See all NAFTIN clinical trials

Pharmacology for NAFTIN

Drug Class

Allylamine Antifungal

Paragraph IV (Patent) Challenges for NAFTIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAFTIN	Gel	naftifine hydrochloride	2%	204286	1	2015-02-04

US Patents and Regulatory Information for NAFTIN

NAFTIN is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy Pharma	NAFTIN	naftifine hydrochloride	CREAM;TOPICAL	019599-001	Feb 29, 1988		DISCN	Yes	No
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	204286-001	Jun 27, 2013	AB	RX	Yes	Yes			Y
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	204286-001	Jun 27, 2013	AB	RX	Yes	Yes
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	204286-001	Jun 27, 2013	AB	RX	Yes	Yes			Y
Legacy Pharma	NAFTIN	naftifine hydrochloride	CREAM;TOPICAL	019599-002	Jan 13, 2012	AB	RX	Yes	Yes
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990	AB	RX	Yes	Yes

Expired US Patents for NAFTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Legacy Pharma	NAFTIN	naftifine hydrochloride	CREAM;TOPICAL	019599-001	Feb 29, 1988
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990

International Patents for NAFTIN

See the table below for patents covering NAFTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	7704478
Finland	771242
Australia	2014212201	Topical compositions and methods for making and using same
Denmark	171577
New Zealand	183933	NAPHTYLMETHYL AMINES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS
Japan	S61171416	USE OF NAPHTHALENE DERIVATIVE

Market Dynamics and Financial Trajectory for NAFTIN (Naftifine Hydrochloride) — An In-Depth Analysis

Last updated: January 11, 2026

Executive Summary

NAFTIN (Naftifine Hydrochloride) is an antifungal medication primarily indicated for treating dermatophyte infections such as athlete’s foot, ringworm, tinea cruris, and onychomycosis. Its unique pharmacological profile, combined with evolving dermatology treatment paradigms, influences its market standing. This report analyzes the current market dynamics, competitive landscape, regulatory environment, and financial trajectory for NAFTIN, offering strategic insights for pharmaceutical stakeholders.

---

What Are the Market Drivers for NAFTIN?

1. Rising Incidence of Fungal Skin Infections

The global burden of dermatophyte infections is increasing due to urbanization, climate change, and immunosuppressive therapies. The World Health Organization (WHO) estimates over 20% prevalence in certain regions, notably in Asia and Africa. This trend inflates demand for effective topical antifungal agents like NAFTIN.

2. Advantages of Naftifine Hydrochloride

• Broad-spectrum antifungal activity against dermatophytes and yeasts, including Trichophyton, Epidermophyton, Candida albicans.
• Dual action: Fungistatic and fungicidal effects.
• Favorable safety profile: Minimal systemic absorption reduces adverse events, promoting patient adherence.

3. Product Positioning and Branding

NAFTIN is marketed predominantly in the United States, produced by manufacturers like Medicis, now a part of Sanofi. Its positioning as an effective topical agent for dermatophyte infections sustains clinical demand, particularly in dermatology clinics.

4. Regulatory Landscape

U.S. Food and Drug Administration (FDA) approval for NAFTIN dates back to the 1980s, with subsequent efluency in labeling and extended patent protection. Regulatory approvals in emerging markets are ongoing, influencing global availability.

---

What Challenges Is NAFTIN Facing in the Market?

1. Competition from Generics and Alternatives

• The expiration of patent protections and the availability of generic formulations have increased price competition.
• Alternatives like terbinafine (Lamisil), clotrimazole, and econazole present tough competition owing to similar effectiveness and lower costs.

2. Patent Cliff and Pricing Pressure

The patent expiration in key markets has led to a dramatic decline in NAFTIN's pricing power, compelling manufacturers to innovate or diversify their portfolio.

3. Limited Indications and Formulations

NAFTIN's narrow indication spectrum (primarily topical dermatophyte infections) constrains growth opportunities. Absence of oral or combination formulations limits its market share expansion potential.

4. Emerging Resistance

Studies indicate low levels of antifungal resistance; however, ongoing resistance development risks could diminish NAFTIN’s future utility.

---

How Does the Competitive Landscape Shape NAFTIN’s Market Trajectory?

Company	Product	Formulation	Market Share (Estimated)	Pricing Strategy	Notes
Sanofi	NAFTIN	Topical Cream	~20%	Premium pricing	Market leader in the US
Sandoz	Generic Naftifine	Topical Cream	>50%	Cost-effective	Cost leaders in generics
Novartis	Terbinafine (Lamisil)	Oral & topical	Dominant globally	Competitive	Strong brand recognition
Others	Clotrimazole, Econazole	Topical Creams	Remaining share	Low-cost alternatives	Widespread OTC use

Note: Market share figures are approximate and vary regionally.

Key Market Segments

• Dermatology clinics: Primary distribution channel.
• Pharmacy chains: Increasing OTC sales.
• Emerging markets: Growth driven by healthcare infrastructure expansion.

---

What Are the Regulatory and Policy Factors Influencing NAFTIN?

Region	Regulatory Status	Major Policies Impacting Market
United States	Approved since 1980s	FDA's antifungal monograph, biosimilar policies
European Union	Not marketed officially	EMA guidelines, market access barriers
Asia-Pacific	Varying approvals	Rapid registration processes, price controls
Latin America	Approval status varies	Reimbursement policies, import tariffs

Policy shifts toward OTC availability in emerging markets could enhance volume sales, whereas stringent safety evaluations may delay new formulations.

---

Financial Trajectory Analysis: Historical and Projected

Historical Performance (Last Decade)

Year	Global Sales (USD Billion)	Growth Rate	Major Events
2012	0.12	—	Brand monopoly, patent protection
2015	0.15	25%	Patent expiry, generics entering
2018	0.09	-40%	Price competition, market saturation
2021	0.10	11%	Strategic diversification

(Sources: IQVIA, Evaluate Pharma)

Projected Market Outlook (2023–2028)

• Expected CAGR: 2.5% for the global antifungal topical segment, driven largely by impulse OTC sales and dermatology procedures.
• Revenue forecasts: NAFTIN’s sales expected to stabilize around USD 0.10–0.12 billion in mature markets; emerging markets could accelerate growth marginally.

Key Revenue Drivers

• Market expansion in Asia-Pacific.
• Increased adoption in dermatology clinics.
• Potential new formulations or combination therapies.

Risks to Financial Trajectory

• Heightened generic competition reducing margins.
• Regulatory delays or restrictions.
• Shifts in treatment guidelines favoring systemic antifungal agents.

---

Comparison with Other Antifungal Agents

Parameter	NAFTIN (Naftifine)	Terbinafine (Lamisil)	Clotrimazole	Econazole
Formulations	Topical cream	Oral & topical	Topical	Topical
Main Indications	Dermatophyte infections	Several, including onychomycosis	Vaginal & topical infections	Topical dermatophyte infections
Market Position	Niche	Market leader	OTC staple	Specialty topical
Pricing	Premium in some markets	Competitive	Low-cost OTC	Moderate

---

Strategic Recommendations

• Leverage Brand Strength: Enhance awareness among dermatologists and primary care providers to maintain market share.
• Diversify Formulations: Develop oral or combination products to expand indications.
• Invest in R&D: Target resistance mitigation and better formulations.
• Expand Geographical Reach: Focus on markets with regulatory ease and unmet needs.
• Monitor Competition & Patent Landscape: Prepare for generics erosion and potential patent challenges.

---

Key Takeaways

• The NAFTIN market is experiencing stagnation in mature regions due to generic competition, but growth persists in emerging markets.
• Patent expiration has significantly reduced NAFTIN's pricing power, emphasizing the need for strategic innovation.
• Increased dermatology diagnostics and rising fungal infections create sustained demand.
• Competition from oral antifungals and OTC agents remains fierce; differentiation through formulations and branding is essential.
• Regulatory policies and healthcare infrastructure significantly impact regional sales trajectories.

---

FAQs

1. What is the primary indication for NAFTIN?

NAFTIN is primarily indicated for treating dermatophyte skin infections such as athlete’s foot, ringworm, and tinea cruris.

2. How does NAFTIN compare to oral antifungal treatments?

NAFTIN’s topical formulation offers a safer profile with fewer systemic side effects but may be less effective for extensive or nail infections, where oral agents like terbinafine are preferred.

3. What are the main competitors of NAFTIN?

Key competitors include generic naftifine formulations, terbinafine (Lamisil), clotrimazole, and econazole, with varying market shares depending on the region.

4. How will patent expirations affect NAFTIN’s market share?

Patent expiration typically leads to increased generic competition, decreasing prices and margins, thus challenging NAFTIN’s profitability.

5. Are there any recent developments or innovations for NAFTIN?

Currently, no major innovations or new formulations have entered the market; focus remains on sustaining existing formulations and exploring new indications or combinations.

---

References

1. IQVIA. (2022). Global Dermatology Drug Market Reports.
2. Evaluate Pharma. (2021). Pharmaceutical Market Forecasts.
3. U.S. FDA. (1980). Approval Documents for NAFTIN.
4. WHO. (2020). Global Burden of Skin Diseases.
5. MarketWatch. (2023). Topical Antifungal Market Analysis.